PCN33 ECONOMIC EVALUATION OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) BASED ON IRINOTECAN (FOLFIRI) + BEVACIZUMAB OR CETUXIMAB, ADJUSTED BY KRAS GENE (WILD-TYPE (WT) OR MUTANT (MT))

✍ Scribed by L Torrecillas; J Vargas

• Book ID: 119597421
• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: English
• Weight: 99 KB
• Volume: 11
• Category: Article
• ISSN: 1098-3015
• DOI: 10.1016/s1098-3015(10)66570-9